Revenue cycle management solutions provider MBX Medical Billing Experts has rolled out a new healthcare data analytics tool aimed at helping provider organizations maximize financial and operational ...

MBX Biosciences, Inc. ( ($MBX) ) has shared an announcement. On September 4, 2025, MBX Biosciences announced the dosing of the first participant ...

CARMEL, Ind., June 16, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ...

MBX Biosciences Inc. (NASDAQ:MBX) is one of the best IPO stocks to buy according to Wall Street analysts. On June 16, MBX Biosciences announced the submission of an Investigational New Drug/IND ...

MBX Biosciences (MBX) announced the publication of a peer-reviewed article highlighting results from the Phase 1 study of MBX 2109, the Company’s parathyroid hormone peptide prodrug in development for ...

Carmel-based MBX Biosciences Inc. saw it shares jump nearly 48% in its debut Friday on the Nasdaq. The five-year-old company is developing treatments for endocrine and metabolic disorders, such as ...

MBX Biosciences has added to the recent flurry of IPO filings. The biotech, which filed its paperwork weeks after raising $63.5 million privately, is seeking funding to take a would-be challenger to ...

CARMEL, Ind.--(BUSINESS WIRE)--MBX Biosciences, a drug discovery company focused on rare endocrine diseases, today announced the appointment of Mary Jane Geiger, M.D., Ph.D., FACP, FAHA, to the newly ...

CARMEL, Ind. - MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company with a market capitalization of $347 million, has submitted an Investigational New Drug (IND) application ...